PROK — ProKidney Corp.
NASDAQ · Healthcare · Biotechnology
$1.88
+$0.03 (+1.62%)
ProKidney Corp. (PROK) is a biotechnology company listed on NASDAQ. It is led by Bruce Culleton M.D., based in 2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States, 27103, with about 231 employees. ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Net income was -$35.8M. PROK currently screens at market cap $543.7M.
Use this PROK page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PROK quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PROK SEC filings page. Lician reads the product cache first so this HTML stays unique to ProKidney Corp. even when a live quote feed is slow.
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Key Statistics
Market Cap
$543.71M
Volume
745,214
Previous Close
$1.61
Day Range
$1.62 – $1.75
EPS
$0.00
Revenue
$0.00
Net Income
-$163.34M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
231
PROK Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$163.34M | -$135.45M | -$54.50M | -$55.15M |
| EPS (Diluted) | $0.00 | $0.00 | -$0.23 | $0.00 |
Total Assets
$441.07M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$99.12M
Operating Cash Flow
-$126.35M
Free Cash Flow
$0.00
ProKidney Corp. Company Information
- CEO & Director
- Bruce Culleton M.D.
- Headquarters
- 2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States, 27103
- Website
- prokidney.com
- Phone
- 336 999 7019
- IPO / Founded
- 2022-07-12
- Sector
- Healthcare
- Industry
- Biotechnology